What is the optimal clinical endpoint for microneedling procedures?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Optimal Clinical Endpoint for Microneedling

The Global Aesthetic Improvement Scale (GAIS) should be your primary clinical endpoint for microneedling procedures, as it provides standardized, blinded dermatologist assessment and correlates with patient satisfaction across multiple indications. 1

Rationale for GAIS as Primary Endpoint

The 2025 guideline from Periodontology 2000 establishes GAIS as a core outcome measure, using a 5-point scale (no improvement, mild, moderate, marked, excellent improvement) assessed by blinded dermatologists 1. This endpoint demonstrates:

  • Objective assessment: Blinded evaluator reduces bias
  • Clinical relevance: Directly measures aesthetic improvement
  • Standardization: Consistent across studies and indications
  • Correlation with efficacy: Higher GAIS scores align with histologic improvements (increased dermal thickness, neocollagenosis, enhanced collagen organization) 1

Recent research confirms GAIS superiority—a 2026 facial rejuvenation study showed GAIS scores significantly differentiated treatment groups (p < 0.001), with layering technique achieving superior outcomes 2. Similarly, a 2024 acne scar study demonstrated GAIS effectively captured treatment response, with 81% achieving good-to-optimal improvement 3.

Complementary Secondary Endpoints

While GAIS should be primary, combine it with condition-specific measures:

For Facial Rejuvenation:

  • Wrinkle Severity Rating Scale (WSRS): 0-5 grading system for wrinkle depth 1
  • Fitzpatrick Wrinkle and Laxity Classification Scale (FWCS): Demonstrated significant discrimination between treatment groups in 2026 study 2
  • Patient satisfaction: Quartile scale or VAS 1, 4

For Acne Scars:

  • Goodman and Baron Scale (GBS) or ECCA Grading Scale: Quantifies scar severity 1, 3
  • Manchester Scar Scale (MSS): Assesses distortion, color, and texture 5

For Striae:

  • Manchester Scar Scale: Showed 43.89% improvement for striae rubrae at 3 months 5

Objective Measurement Tools

Enhance subjective scales with objective data:

  • VISIA-CR System: High-resolution photography for spots, wrinkles, texture, pores 1
  • Ultrasound (16 MHz): Measures dermal thickness changes 1
  • Antera 3D Camera: Quantifies skin surface changes 1
  • Cutometer: Assesses skin elasticity/rebound rate 2

Critical Timing Considerations

Assess outcomes at 3 months post-final treatment as your primary timepoint. The evidence shows:

  • Improvements continue progressively for 6 months post-treatment due to ongoing neocollagenesis 6
  • 3-month assessment captures substantial improvement while maintaining practical follow-up 2, 5, 3
  • Earlier timepoints (1-2 months) underestimate final outcomes 1, 2

The 2026 striae study demonstrated continued improvement between 3 and 6 months (48.89% vs 43.89% MSS improvement for striae rubrae) 5, but 3 months provides adequate assessment for clinical decision-making.

Common Pitfalls to Avoid

Do not rely solely on patient satisfaction—while important, it lacks standardization and objectivity. The 2025 guideline notes "no standardised assessment score across all trials" led to heterogeneous, difficult-to-compare results 1.

Do not assess too early—transient erythema and immediate post-procedure changes confound assessment. Wait minimum 1 month, preferably 3 months 1, 2.

Do not use single-dimension scales—wrinkle assessment alone misses texture, pore, and elasticity improvements. GAIS captures global aesthetic change 1, 2.

Practical Implementation Algorithm

  1. Baseline: Document GAIS, condition-specific scale (WSRS/GBS/MSS), VISIA imaging, patient satisfaction
  2. During treatment: Monitor adverse events only (erythema, scaling, pruritus expected and transient) 4, 7
  3. 1 month post-final treatment: Interim GAIS and patient satisfaction
  4. 3 months post-final treatment: PRIMARY ENDPOINT—Complete GAIS by blinded assessor, all secondary measures, photography
  5. 6 months (optional): Extended follow-up for research or severe cases

For acne specifically: The guideline recommends 3 treatments 1 month apart, then maintenance every 6 months 1. Assess at 3 months after initial series.

This approach prioritizes quality of life through validated aesthetic improvement scales while maintaining objective measurement standards.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.